Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SYNDROS vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
FDA: Chemotherapy-induced nausea and vomiting (CINV) refractory to conventional antiemetics,FDA: Anorexia associated with weight loss in patients with acquired immunodeficiency syndrome (AIDS)
Mild to moderate pain,Fever
5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life is 28–61 hours (mean ~32 hours) in adults; prolonged with high-fat meal. Clinical context: Steady state achieved in 5–6 days.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via cytochrome P450 (CYP) 3A4 and 2C9 isoenzymes; undergoes extensive first-pass metabolism to active and inactive metabolites.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Approximately 65% of a dose is excreted in feces (primarily as hydroxylated and carboxylated metabolites) and 35% in urine (as metabolites, with <5% unchanged drug).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
97–99% bound, primarily to albumin and lipoproteins.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Vd: 10–80 L/kg (mean ~30 L/kg), indicating extensive tissue distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral bioavailability: ~10–20% (variable due to extensive first-pass metabolism); increased 2- to 4-fold with a high-fat meal.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No dose adjustment required for mild to moderate renal impairment; insufficient data for severe impairment (e GFR <30 m L/min); use with caution.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to potential for encephalopathy.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Safety and efficacy not established in pediatric patients; not recommended under 18 years.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment; monitor for increased sensitivity to adverse effects (e.g., dysphoria, hypotension).
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Risk of psychiatric adverse reactions, including dysphoria, hallucinations, paranoia, and worsening of pre-existing mental illness,Central nervous system depressant effects and impairment of cognitive function, motor skills, and judgment; caution when driving or operating machinery,Potential for abuse, tolerance, and dependence (Schedule III controlled substance),May increase heart rate and blood pressure; use with caution in patients with cardiovascular disease,Seizures: May lower seizure threshold in patients with epilepsy,Pancreatitis: Cases reported; monitor for symptoms
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to dronabinol or any cannabinoid or sesame oil (capsule contains sesame oil),Concurrent use with disulfiram or metronidazole due to alcohol content in oral solution (however, Syndros is a dronabinol solution; contraindication applies to alcohol-containing formulations – note: Syndros contains alcohol; label contraindicates concurrent use with disulfiram or metronidazole)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Food with high fat content may increase dronabinol absorption; take consistently with or without food to avoid variability. Grapefruit and grapefruit juice may increase dronabinol levels; avoid concurrent use.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a small increased risk of neural tube defects. Second and third trimester exposure may affect fetal brain development, including potential long-term neurobehavioral effects. Dronabinol crosses the placenta. Use only if potential benefit justifies potential risk to the fetus.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Dronabinol is excreted into human milk. The M/P ratio is not specifically determined for dronabinol; however, THC (active component) has an M/P ratio of approximately 0.04 based on limited data. Because of the potential for adverse effects on the nursing infant, such as developmental delay and sedation, breastfeeding is not recommended during SYNDROS therapy. An alternative method of infant feeding should be considered.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce dronabinol concentrations. However, due to lack of systematic dose-response data and potential fetal risks, routine dose increments are not recommended. The lowest effective dose should be used. If clinical response is suboptimal, consider non-pharmacologic alternatives. Do not exceed maximum recommended doses (20 mg/day).
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Syndros (dronabinol oral solution) is a synthetic delta-9-tetrahydrocannabinol (THC) used for chemotherapy-induced nausea and vomiting (CINV) and anorexia with weight loss in AIDS patients. It has a high first-pass metabolism; avoid use in patients with hepatic impairment. Onset is faster than capsules; dosing must be individualized based on prior cannabis exposure. Monitor for CNS depression and avoid concurrent use with other CNS depressants. Syndros contains alcohol (5% v/v); use cautiously in patients with alcohol intolerance or liver disease. Contraindicated in patients with a history of hypersensitivity to THC or sesame oil (vehicle).
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take Syndros 1 to 3 hours before chemotherapy for CINV, or twice daily before lunch and dinner for AIDS-related anorexia.,Avoid driving or operating machinery until you know how Syndros affects you, as it can cause dizziness, drowsiness, and altered judgment.,Do not drink alcohol or take other sedating medications while using Syndros, as this increases the risk of severe sedation.,Report any mood changes, depression, or suicidal thoughts to your healthcare provider immediately.,Store at room temperature (20-25°C) and protect from light; do not freeze.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss use with your doctor; THC can pass into breast milk.,Use a calibrated measuring device for the oral solution (provided with the medication) to ensure accurate dosing.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SYNDROS vs ACEPHEN, answered by our medical review team.
SYNDROS is a Cannabinoid that works by Dronabinol is a cannabinoid receptor type 1 (CB1) agonist, activating CB1 receptors in the central nervous system to inhibit emetic signals and stimulate appetite. It also has partial agonist activity at cannabinoid receptor type 2 (CB2).. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SYNDROS and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SYNDROS is: 5 mg/m² orally 1-3 hours before chemotherapy, initially; may increase by 2.5 mg/m² increments as tolerated, maximum 15 mg/m² per dose.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SYNDROS and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SYNDROS is classified as Category C. Dronabinol (SYNDROS) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and fetotoxicity at doses similar to human therapeutic doses. There are no . ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.